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INTRODUCTION
Type 2 neurofibromatosis (NF2) is an 
autosomal dominant disease with a frequency 
of 0.5/100,000 inhabitants; it manifests mainly as 
bilateral vestibular schwannomas and bilateral 
profound hearing loss.
Brainstem implants have been the main 
hearing rehabilitation method in these patients.1 
Although this approach is a significant advance 
in the treatment of these patients, the qualitative 
results of brainstem implants are more limited 
than those of cochlear implants.2 Loss of electri-
cal stimulus processing in the cochlea (by cells in 
the spiral ganglion and cochlear nerve) and the 
difficulty of positioning electrodes in the fourth 
ventricle explain a poorer hearing performance 
with brainstem implants.3
The past decades have witnessed refine-
ments in the results of surgeries for the treatment 
of vestibular schwannomas. The possibility of 
preserving the cochlear nerve in neurofibromatosis 
cases makes it feasible to fit cochlear implants for 
improved auditory rehabilitation.2,4,5
We present the results attained in a pa-
tients with neurofibromatosis in whom the neo-
plasm was removed and a cochlear implant was 
placed simultaneously. Based on a review of the 
literature, this is the first documented case of this 
procedure in Brazil.
CASE REPORT
HC, a white male student aged 23 years, 
diagnosed with neurofibromatosis type 2, devel-
oped significant hearing loss to the right, which 
was associated with tumor growth in that side. 
The tumor was removed surgically in 2005, but the 
patient progressed to total hearing loss. In 2008, 
the patients noticed marked hearing loss to the left, 
diagnosed as profound hearing loss due to growth 
of the ipsilateral tumor (Fig. 1, lower left detail). 
Imaging showed also a meningioma located pos-
terior to the inner auditory canal (Fig. 1).
Simultaneous surgery and brainstem 
implant were indicated. The patient did not want 
the brainstem implant, and it was agreed that if the 
cochlear nerve remained intact, a cochlear implant 
would be fitted.
Translabyrinthine surgery was uneventful; 
the meningioma and the vestibular schwannoma 
were removed, and the facial and cochlear nerves 
were preserved; a cochlear implant was placed. In-
traoperative neural telemetry confirmed consistent 
responses in all electrodes.
The facial nerve remained functional. 
Imaging for control purposes demonstrated that 
the tumors had been adequately removed. Af-
ter 6 months of cochlear implant use, the pure 
tone threshold was around 30 dB, monosyllable 
discrimination was 56%, and open set sentence 
discrimination was 100% (Fig. 1, lower right detail).
DISCUSSION
Treating patients with neurofibromatosis 
type 2 remains a difficult task. Fortunately, sat-
isfactory results have currently been attained in 
the treatment of this disease, and patients have 
become more concerned with their quality of life. 
Approaches to restore hearing should always be 
taken into account when treating neurofibromato-
sis type 2, as bilateral profound hearing loss is an 
almost universal event in this condition. Brainstem 
implants have been the main choice for many years, 
and have yielded interesting but limited results in 
language discrimination.1,2,4,5 Reports of cochlear 
implant use in patients with neurofibromatosis type 
2 have shown that they are superior to brainstem 
implants for increasing auditory abilities and for 
sustaining these results in the long term.2,5 There-
fore, cochlear implants have become an option in 
such circumstances. The indispensable condition 
for this approach is that the anatomy and func-
tion of the cochlear nerve be preserved. From a 
surgical perspective, anatomical preservation may 
be attained with careful microsurgical techniques, 
and preferably operating smaller tumors. This 
should be taken into account in the treatment of 
neurofibromatosis; thus, surgery for less developed 
tumors with milder forms of hearing loss may be 
considered if the cochlear nerve is to be preserved - 
especially if the possibility of contralateral auditory 
rehabilitation is absent. Determining the functional 
viability of the cochlear nerve is more complex. 
Electric stimulation tests of the promontory are 
still employed, but are rather subjective.2 The pos-
sibility of carrying out electrically evoked auditory 
potentials seems to us more adequate, but this test 
is not routinely available.6
Finally, cochlear implants are safer than 
brainstem implants in terms of the eventual ad-
verse effects of electrical stimulation; they are also 
less costly, and it is more practical to maintain its 
programming and electronic components. Further-
more, cochlear implants may be used in patients 
that live far from tertiary care or high complexity 
healthcare centers.
Our case of a young patients with bilateral 
hearing loss that had already been operated, with-
out hearing rehabilitation, benefited significantly 
from a cochlear implant fitter immediately after 
removing his second vestibular schwannoma, 
enjoying improved quality of life.
FINAL COMMENTS
Fitting a cochlear implant is an approach 
to be considered in the surgical planning of 
neurofibromatosis type 2 patients with bilateral 
schwannomas. This may be justified because of 
the superior auditory results that this technique 
provides compared to brainstem implants, as 
well as more safety and easier maintenance and 
programming.
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Figure 1. Magnetic resonance imaging (T1 contrast) showing 
a vestibular schwannoma to the left (white arrow) associated 
with a meningioma on the medial aspect of the left petrous bone 
(black arrow). Note also small manipulation remains in the right 
pontocerebellar angle. On the lower left detail, see preoperative 
audiometry. On the lower right detail see audiometry 6 months 
after the cochlear implant.
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